Personalis, Inc. (Nasdaq: PSNL) has announced multiple upcoming presentations featuring their NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) assay at two major oncology conferences. The genomics company and its academic partners will present the latest data on the test's ability to detect residual and recurrent cancer at both the American Association for Cancer Research (AACR) Annual Meeting in April and the American Society of Clinical Oncology (ASCO) Annual Meeting in June.
The presentations will showcase clinical evidence for the NeXT Personal assay across more than 15 different cancer types, with a particular focus on colorectal, lung, breast, and cervical cancers.
AACR Presentations Highlight Colorectal and Lung Cancer Applications
At the AACR meeting in Chicago, two oral presentations will feature significant findings from major clinical studies. The VICTORI study will present preliminary results on post-surgical minimal residual disease (MRD) detection in colorectal cancer patients, presented by Emma Titmuss from BC Cancer in Vancouver.
Additionally, results from the TRACERx collaboration, described as one of the largest ctDNA studies in early-stage lung cancer, will be presented by Charles Swanton from The Francis Crick Institute in London.
"With a more sensitive test, our goal is to improve patient outcomes by finding and treating colorectal cancer recurrence earlier," said Dr. Richard Chen, Chief Medical Officer and Executive Vice President of R&D at Personalis.
A poster presentation at AACR will also detail results from clinical NeXT Personal testing across more than 15 different cancer types, demonstrating the test's real-world impact on MRD detection.
ASCO Presentations Expand Evidence in Breast and Cervical Cancers
The following month at the ASCO Annual Meeting, Personalis will present new data expanding the clinical evidence for NeXT Personal into additional cancer types and treatment settings.
"These studies continue to expand the clinical data for NeXT Personal into new areas, including neoadjuvant treatment in breast cancer and cervical cancer," noted Dr. Chen. "We continue to be driven by our mission to provide physicians and their patients better tools for guiding treatment through earlier, more sensitive, and more accurate detection of residual and recurrent cancer."
The PREDICT-DNA trial (TBCRC 040) will present its first results examining the relationship between ctDNA, pathologic response after neoadjuvant therapy, and survival in breast cancer patients. This presentation will be delivered by Dr. Natasha Hunter from the University of Washington.
Another significant oral presentation will focus on ultrasensitive detection and tracking of ctDNA in locally advanced cervical cancer, featuring analyses from the Phase 3 CALLA trial. Dr. Jyoti Mayadev from the University of California San Diego Medical Center will present findings on the association between ctDNA detection and relapse and survival outcomes.
Additional poster presentations at ASCO will explore the prognostic value of ultrasensitive ctDNA detection in triple-negative breast cancer following neoadjuvant chemotherapy, as well as the use of ctDNA monitoring to identify early predictors of immunotherapy success in advanced cancer.
Clinical Significance of Ultrasensitive ctDNA Testing
The NeXT Personal assay is designed to detect minimal residual disease and cancer recurrence at the earliest possible timepoints. This technology aims to transform cancer management by providing physicians with highly sensitive tools to guide treatment decisions throughout the patient journey.
By detecting cancer recurrence earlier than conventional methods, the test could potentially enable more timely interventions and improve patient outcomes. The presentations at both conferences will provide important clinical validation for this approach across multiple cancer types and treatment settings.
Personalis positions its technology as part of a new paradigm for cancer management, where ultrasensitive genomic testing can detect disease even as cancer evolves over time. Beyond MRD detection, the company's products also enable selection of targeted therapies based on comprehensive genomic profiling and enhance biomarker strategies for drug development.
As these presentations demonstrate, the company continues to build clinical evidence supporting the utility of its NeXT Personal assay in various oncology applications, potentially expanding the role of liquid biopsy testing in cancer care.
